FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke.
A recently described coagulation disorder [FV-Arg-506-Gln-mutation-associated resistance to activated protein C (APC-resistance)] leads to a five- to tenfold increased risk for venous thromboembolism. The aim of the study was to determine if this disorder also predisposes to ischemic stroke. Ninety-nine consecutive patients with ischemic stroke of noncardiac origin were screened for APC-resistance and tested for the FV-Arg-506-Gln mutation. The FV-Arg-506-Gln mutation was found in 5 of the 99 stroke patients and in 6% of a pool of blood donors. FV-Arg-506-Gln mutation is not a major cause of ischemic stroke. However, a minor predisposing effect cannot be excluded. Further studies with larger stroke populations and subpopulations are indicated to determine the exact impact of this condition on ischemic stroke.
Department of Neurology, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland.
T
T
Tatlisumak
Department of Neurology, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland; Department of Clinical Chemistry, Helsinki University, Haart-maninkatu, Helsinki, Finland.
M
M
Syrjälä
Laboratory Department, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland.
P
P
Lindsberg
Laboratory Department, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland; Department of Clinical Chemistry, Helsinki University, Haart-maninkatu, Helsinki, Finland.
A
A
Palotie
Department of Neurology, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland.
M
M
Kaste